Evidence map›Paper›PMID 31783895›Full record

ArticleBreast cancer research : BCR2019

Cross-talk between SIM2s and NFκB regulates cyclooxygenase 2 expression in breast cancer.

Garhett L Wyatt, Lyndsey S Crump, Chloe M Young, Veronica M Wessells, Cole M McQueen, Steven W Wall, Tanya L Gustafson, Yang-Yi Fan, Robert S Chapkin, Weston W Porter and 1 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Loss of STING impairs lactogenic differentiation.Development (Cambridge, England) · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Garhett L WyattDepartment of Integrative Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX, USA.
Lyndsey S CrumpDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, USA.
Chloe M YoungDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, USA.
Veronica M WessellsDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, USA.
Cole M McQueenDepartment of Integrative Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX, USA.
Steven W WallDepartment of Integrative Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX, USA.
Tanya L GustafsonDepartment of Integrative Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX, USA.
Yang-Yi FanDepartment of Nutrition, Texas A&M University, College Station, TX, USA.
Robert S ChapkinDepartment of Nutrition, Texas A&M University, College Station, TX, USA.
Weston W PorterDepartment of Integrative Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX, USA. wporter@cvm.tamu.edu.
Traci R LyonsDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, USA. traci.lyons@ucdenver.edu.ORCID 0000-0002-8876-0391
Texas A&M University · USUniversity of Colorado Cancer Center · US

Funding

Deciphering COX-2/SEMA7A dependent mechanisms of breast tumor progression.R01CA211696 · NCI · UNIVERSITY OF COLORADO DENVER · PI LYONS, TRACI · 2017 to 2021
$2.0M
Circadian regulation of PAH metabolismR01ES025209 · NIEHS · TEXAS A&M AGRILIFE RESEARCH · PI PORTER, WESTON W · 2015 to 2019
$1.6M
Transcriptional regulation of differentiation gene expressionR01HD083952 · NICHD · TEXAS A&M AGRILIFE RESEARCH · PI PORTER, WESTON W, RIJNKELS, MONIQUE · 2016 to 2020
$1.5M
(PQA1)Toward understanding mechanisms of COX-2 driven metastasis of breast cancerR21CA185226 · NCI · UNIVERSITY OF COLORADO DENVER · PI LYONS, TRACI · 2014 to 2015
$371k
Diet-dependent regulation of DCIS progressionR21CA197896 · NCI · TEXAS A&M AGRILIFE RESEARCH · PI PORTER, WESTON W · 2016 to 2017
$355k
Hormonal Regulation and Tumor Promotional Phenotypes of Semaphorin 7a in Breast CancerF31CA236140 · NCI · UNIVERSITY OF COLORADO DENVER · PI CRUMP, LYNDSEY S · 2019 to 2021
$91k
NCI NIH HHS F31 CA236140NCI NIH HHS R01 CA211696NCI NIH HHS R21 CA185226NCI NIH HHS R21 CA197896NICHD NIH HHS R01 HD083952NIEHS NIH HHS R01 ES025209
6 · The paper itself

Abstract

backgroundBreast cancer is a leading cause of cancer-related death for women in the USA. Thus, there is an increasing need to investigate novel prognostic markers and therapeutic methods. Inflammation raises challenges in treating and preventing the spread of breast cancer. Specifically, the nuclear factor kappa b (NFκB) pathway contributes to cancer progression by stimulating proliferation and preventing apoptosis. One target gene of this pathway is PTGS2, which encodes for cyclooxygenase 2 (COX-2) and is upregulated in 40% of human breast carcinomas. COX-2 is an enzyme involved in the production of prostaglandins, which mediate inflammation. Here, we investigate the effect of Singleminded-2s (SIM2s), a transcriptional tumor suppressor that is implicated in inhibition of tumor growth and metastasis, in regulating NFκB signaling and COX-2.

methodsFor in vitro experiments, reporter luciferase assays were utilized in MCF7 cells to investigate promoter activity of NFκB and SIM2. Real-time PCR, immunoblotting, immunohistochemistry, and chromatin immunoprecipitation assays were performed in SUM159 and MCF7 cells. For in vivo experiments, MCF10DCIS.COM cells stably expressing SIM2s-FLAG or shPTGS2 were injected into SCID mice and subsequent tumors harvested for immunostaining and analysis.

resultsOur results reveal that SIM2 attenuates the activation of NFκB as measured using NFκB-luciferase reporter assay. Furthermore, immunostaining of lysates from breast cancer cells overexpressing SIM2s showed reduction in various NFκB signaling proteins, as well as pAkt, whereas knockdown of SIM2 revealed increases in NFκB signaling proteins and pAkt. Additionally, we show that NFκB signaling can act in a reciprocal manner to decrease expression of SIM2s. Likewise, suppressing NFκB translocation in DCIS.COM cells increased SIM2s expression. We also found that NFκB/p65 represses SIM2 in a dose-dependent manner, and when NFκB is suppressed, the effect on the SIM2 is negated. Additionally, our ChIP analysis confirms that NFκB/p65 binds directly to SIM2 promoter site and that the NFκB sites in the SIM2 promoter are required for NFκB-mediated suppression of SIM2s. Finally, overexpression of SIM2s decreases PTGS2 in vitro, and COX-2 staining in vivo while decreasing PTGS2 and/or COX-2 activity results in re-expression of SIM2.

conclusionOur findings identify a novel role for SIM2s in NFκB signaling and COX-2 expression.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsBasic Helix-Loop-Helix ProteinsBreast NeoplasmsCell Line, TumorCyclooxygenase 2Disease Models, AnimalFemaleGenes, ReporterHumansImmunohistochemistryMiceMice, KnockoutModels, BiologicalMutationNF-kappa BBasic Helix-Loop-Helix ProteinsCyclooxygenase 2NF-kappa BSIM2 protein, humanBreast cancerCOX-2InflammationNFκBProstaglandin E2SIM2

Identifiers

PMID31783895
PMCPMC6884910
OpenAlexW2990662514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.